KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Moderna (MRNA) Other Non-Current Assets (2017 - 2026)

Moderna (MRNA) has disclosed Other Non-Current Assets for 10 consecutive years, with $675.0 million as the latest value for Q1 2026.

  • For Q1 2026, Other Non-Current Assets rose 21.4% year-over-year to $675.0 million; the TTM value through Mar 2026 reached $675.0 million, up 21.4%, while the annual FY2025 figure was $605.0 million, 1.85% up from the prior year.
  • Other Non-Current Assets hit $675.0 million in Q1 2026 for Moderna, up from $605.0 million in the prior quarter.
  • Across five years, Other Non-Current Assets topped out at $1.3 billion in Q2 2023 and bottomed at $12.0 million in Q1 2022.
  • Average Other Non-Current Assets over 5 years is $603.5 million, with a median of $605.0 million recorded in 2025.
  • Year-over-year, Other Non-Current Assets soared 10650.0% in 2023 and then plummeted 50.31% in 2024.
  • Moderna's Other Non-Current Assets stood at $988.0 million in 2022, then fell by 22.47% to $766.0 million in 2023, then dropped by 22.45% to $594.0 million in 2024, then grew by 1.85% to $605.0 million in 2025, then grew by 11.57% to $675.0 million in 2026.
  • According to Business Quant data, Other Non-Current Assets over the past three periods came in at $675.0 million, $605.0 million, and $530.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.